These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 12501122)

  • 1. Blurred vision.
    Smaglik P
    Nature; 2002 Dec; 420(6916 Suppl):A19, A21, A23. PubMed ID: 12501122
    [No Abstract]   [Full Text] [Related]  

  • 2. Building Nordic networks.
    Smaglik P
    Nature; 2002 Dec; 420(6916 Suppl):A3, A5, A7. PubMed ID: 12501120
    [No Abstract]   [Full Text] [Related]  

  • 3. Berkeley dispute festers over biotech deal.
    Dalton R
    Nature; 1999 May; 399(6731):5. PubMed ID: 10331373
    [No Abstract]   [Full Text] [Related]  

  • 4. Why French politics and science don't mix.
    Nat Mater; 2004 May; 3(5):275. PubMed ID: 15122212
    [No Abstract]   [Full Text] [Related]  

  • 5. Syngenta ready to drop plans for Indian rice venture.
    Jayaraman KS
    Nature; 2002 Dec; 420(6916):596. PubMed ID: 12478254
    [No Abstract]   [Full Text] [Related]  

  • 6. Good neighbours.
    Niiler E
    Nature; 2003 Dec; 426(6967):690-4. PubMed ID: 14668872
    [No Abstract]   [Full Text] [Related]  

  • 7. Syngenta ends plant-research deal with Berkeley.
    Dalton R
    Nature; 2003 Nov; 426(6964):216. PubMed ID: 14628007
    [No Abstract]   [Full Text] [Related]  

  • 8. Golden opportunities.
    Smaglik P
    Nature; 2005 Jul; 436(7047):144-7. PubMed ID: 16007735
    [No Abstract]   [Full Text] [Related]  

  • 9. Marketing biotechnology with a Gallic flair.
    Jouanneau AC
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE36-7. PubMed ID: 12874977
    [No Abstract]   [Full Text] [Related]  

  • 10. Building cooperation New York.
    Smaglik P
    Nature; 2002 Sep; 419(6905):4-5. PubMed ID: 12352990
    [No Abstract]   [Full Text] [Related]  

  • 11. Northern England: rising star.
    Smaglik P
    Nature; 2003 Sep; 425(6956):430-3. PubMed ID: 14508497
    [No Abstract]   [Full Text] [Related]  

  • 12. University spin-offs: opportunity or challenge?
    Peng X
    Nat Mater; 2006 Dec; 5(12):923-5. PubMed ID: 17139301
    [No Abstract]   [Full Text] [Related]  

  • 13. Canadian lab loses Amgen backing.
    Knight J
    Nature; 2002 May; 417(6884):4. PubMed ID: 11986629
    [No Abstract]   [Full Text] [Related]  

  • 14. A fresh start for European science.
    Krull W
    Nature; 2002 Sep; 419(6904):249-50. PubMed ID: 12239542
    [No Abstract]   [Full Text] [Related]  

  • 15. Pinnacles or plateaus?
    Gannon F
    EMBO Rep; 2007 Jul; 8(7):611. PubMed ID: 17603529
    [No Abstract]   [Full Text] [Related]  

  • 16. Commercializing biotechnology in the UK.
    Searle S; Graves B; Towler C
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE33-5. PubMed ID: 12874976
    [No Abstract]   [Full Text] [Related]  

  • 17. Danish biotech centre faces axe.
    Abbott A
    Nature; 2003 Mar; 422(6928):105. PubMed ID: 12634749
    [No Abstract]   [Full Text] [Related]  

  • 18. Developing an intellectual property portfolio for the academic or not-for-profit institution.
    Bloomberg CA
    Nat Biotechnol; 2005 Jan; 23(1):119-21. PubMed ID: 15637626
    [No Abstract]   [Full Text] [Related]  

  • 19. Boston: a magnetic hub.
    Smaglik P
    Nature; 2002 May; 417(6886):4-5. PubMed ID: 12015552
    [No Abstract]   [Full Text] [Related]  

  • 20. Poland tackles science like a business.
    Kudrycka B
    Nature; 2008 May; 453(7194):438. PubMed ID: 18497783
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.